51
|
Yang J., Wu Y, Hirsh V, O’Byrne K, Yamamoto N, Popat S, Tamiya A, Kaen D, Märten A, Schuler M. P06 Competing CNS or Systemic Progression Analysis for EGFR Mutation-Positive NSCLC Patients on Afatinib in LUX-Lung 3, 6, and 7. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.07.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
52
|
Markus M, Streibelt M, Schuler M, Gerlich C, Bethge M. Wirksamkeit medizinisch-beruflich orientierter Rehabilitation in der orthopädischen Versorgungsrealität. DAS GESUNDHEITSWESEN 2018. [DOI: 10.1055/s-0038-1667737] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
53
|
Heß V, Schuler M, Meng K, Schulte T, Bengel J, Faller H. Psychosoziale Bedürfnisse und Belastungen bei onkologischen Rehabilitanden: Warum werden sie im Aufnahmegespräch nicht geäußert bzw. erkannt? Psychother Psychosom Med Psychol 2018. [DOI: 10.1055/s-0038-1667991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
54
|
Bethge M, Markus M, Streibelt M, Gerlich C, Schuler M. From evidence to practice: Improving work participation outcomes by work-related medical rehabilitation in patients with chronic musculoskeletal diseases. Ann Phys Rehabil Med 2018. [DOI: 10.1016/j.rehab.2018.05.945] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
55
|
Alma HJ, de Jong C, Jelusic D, Wittmann M, Schuler M, Kollen BJ, Sanderman R, Schultz K, Kocks JWH, Van der Molen T. Assessing health status over time: impact of recall period and anchor question on the minimal clinically important difference of copd health status tools. Health Qual Life Outcomes 2018; 16:130. [PMID: 29940980 PMCID: PMC6019834 DOI: 10.1186/s12955-018-0950-7] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2017] [Accepted: 05/30/2018] [Indexed: 12/17/2022] Open
Abstract
Background The Minimal Clinically Important Difference (MCID) assesses what change on a measurement tool can be considered minimal clinically relevant. Although the recall period can influence questionnaire scores, it is unclear if it influences the MCID. This study is the first to examine longitudinally the impact of the recall period of an anchor question and its design on the MCID of COPD health status tools using the COPD Assessment Test (CAT), Clinical COPD Questionnaire (CCQ) and the St. George’s Respiratory Questionnaire (SGRQ). Methods Moderate to very severe COPD patients without respiratory co-morbidities were recruited during 3-week Pulmonary Rehabilitation (PR). CAT, CCQ and SGRQ were completed at baseline, discharge, 3, 6, 9 and 12 months. A 15-point Global Rating of Change scale (GRC) was completed at each follow-up. A five-point GRC was used as second anchor at 12 months. Mean change scores of a subset of patients indicating a minimal improvement on each of the anchor questions were considered the MCID. The MCID estimates over different time periods were compared with one another by evaluating the degree of overlap of Confidence Intervals (CI) adjusted for dependency. Results In total 451 patients were included (57.9 ± 6.6 years, 65% male, 50/39/11% GOLD II/III/IV), of which 309 completed follow-up. Baseline health status scores were 20.2 ± 7.3 (CAT), 2.9 ± 1.2 (CCQ) and 50.7 ± 17.3 (SGRQ). MCID estimates for improvement ranged − 3.1 to − 1.4 for CAT, − 0.6 to − 0.3 for CCQ, and − 10.3 to − 7.6 for SGRQ. Absolute higher – though not significant – MCIDs were observed for CAT and CCQ directly after PR. Significantly absolute lower MCID estimates were observed for CAT (difference − 1.4: CI -2.3 to − 0.5) and CCQ (difference − 0.2: CI -0.3 to −0.1) using a five-point GRC. Conclusions The recall period of a 15-point anchor question seemed to have limited impact on the MCID for improvement of CAT, CCQ and SGRQ during PR; although a 3-week MCID estimate directly after PR might lead to absolute higher values. However, the design of the anchor question was likely to influence the MCID of CAT and CCQ. Trial registration RIMTCORE trial #DRKS00004609 and #12107 (Ethik-Kommission der Bayerischen Landesärztekammer). Electronic supplementary material The online version of this article (10.1186/s12955-018-0950-7) contains supplementary material, which is available to authorized users.
Collapse
|
56
|
Guberina M, Eberhardt W, Stuschke M, Gauler T, Cheufou D, Schuler M, Stamatis G, Pöttgen C. OC-0493: Pretreatment metabolic volume in PET: Prognostic in lung cancer? German ESPATUE randomised phase3trial. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)30803-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
57
|
Szentes B, Schwarzkopf L, Lehbert N, Wittmann M, Wagner R, Nowak D, Faller H, Schuler M, Schultz K. Is EQ-5D suited to assess quality of life aspects in pulmonary rehabilitation in bronchial asthma. Pneumologie 2018. [DOI: 10.1055/s-0037-1619413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
58
|
Schultz K, Wittmann M, Wagner R, Schwarzkopf L, Nowak D, Faller H, Schuler M. Stimmt der Asthmakontrolltest (ACT) mit den überarbeiteten GINA-Kriterien der Asthmasymptomkontrolle (ASC) überein? Pneumologie 2018. [DOI: 10.1055/s-0037-1619163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
59
|
Ahnert J, Schuler M, Legner R, Schmale R, Berger H, Vogel H. Anträge auf psychosomatische Rehabilitation – Häufigkeit, Qualität und Befürwortungsrate. DAS GESUNDHEITSWESEN 2018; 80:232-239. [DOI: 10.1055/s-0042-106968] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Zusammenfassung
Hintergrund: Der Anteil an psychischen Hauptdiagnosen hat bei den medizinischen Rehabilitationsleistungen der DRV in den letzten Jahren stetig zugenommen. Bisher existieren kaum Daten über Häufigkeit, Qualität und Befürwortungsquote von Anträgen auf eine psychosomatische Reha. Prüfärzte der DRV benötigen im Rehabilitationsantrag ausreichend Informationen über Rehabedarf, -motivation, -fähigkeit und -prognose eines Versicherten. Der ärztliche Befundbericht bei Reha-Anträgen von Patienten mit psychischer Hauptdiagnose wird oft durch den Hausarzt erstellt. Psychische Störungen werden von Hausärzten häufig fehlerhaft diagnostiziert.
Methodik: Bei der DRV Nordbayern und der DRV Bayern Süd wurden über 2 Wochen die prüfärztlichen Entscheidungen bei Reha-Anträgen im Rahmen einer prospektiven Aktenanalyse dokumentiert. Für jeden eingehenden Reha-Antrag wurden folgende Angaben notiert: psychische und somatische Hauptdiagnose/n, Vorliegen von Befundberichten, Angaben zu psychiatrischen/psychotherapeutischen Vorbehandlungen, nachträgliche Anforderung von weiteren Entscheidungsgrundlagen sowie die prüfärztliche Entscheidung.
Ergebnisse: Insgesamt konnten 1 366 Anträge (davon 81% Erstvorlagen) analysiert werden. 16,2% der Erstvorlagen stammen von Antragstellern mit psychischen Hauptdiagnosen. 44,0% dieser Anträge liegt nur ein Befundbericht vom Hausarzt bei. Der Anteil an nicht befürworteten (34,7%) und noch offenen Anträgen (27,2%) liegt bei Reha-Anträgen von Antragstellern mit psychischen Hauptdiagnosen höher als bei Antragstellern mit rein somatischen Hauptdiagnosen (19,6% nicht befürwortete, 12,7% offene Anträge) (χ2=79,8(4), p=0,001). Reha-Anträge von Patienten mit psychischen Hauptdiagnosen ohne Befundbericht vom Psychiater/Psychotherapeuten werden häufiger nicht befürwortet (45,3 vs. 32,3%) oder werden bei der Erstvorlage nicht entschieden (28,0 vs. 18,3%) (χ2=10,2(2), p=0,006). Unter Antragstellern, die bereits in psychiatrischer/psychotherapeutischer Vorbehandlung waren, zeigt sich bei Reha-Anträgen mit Befundbericht vom Hausarzt nur noch ein höherer Anteil an nicht entschiedenen Anträgen (35,7 vs. 18,2%). Bei nicht entschiedenen Anträgen mit Befundbericht vom Hausarzt wird am häufigsten (68,9%) noch ein Befundbericht vom Psychiater/Psychotherapeuten nachgefordert.
Schlussfolgerung: Um die Aussagekraft von Anträgen mit psychischer Erstdiagnose bzw. Anträgen auf eine psychosomatische Rehabilitation zu erhöhen und eine raschere Entscheidung und eine bessere Indikationsstellung zu ermöglichen, könnte es sinnvoll sein, Befundberichte von vornherein von Fachärzten für Psychiatrie oder Psychotherapeuten erstellen zu lassen.
Collapse
|
60
|
Schultz K, Wittmann M, Wagner R, Schwarzkopf L, Nowak D, Schuler M. Tabakentwöhnung (TEW) in der pneumologischen Rehabilitation (PR) von Asthmatikern. Pneumologie 2018. [DOI: 10.1055/s-0037-1619273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
61
|
Mühlig S, Schultz K, Loth F, Schuler M, Wittmann M. Interdependenz von Rauchen und psychischer Komorbidität bei COPD-Patienten: Empirische Daten aus der pneumologischen Rehabilitation. Pneumologie 2018. [DOI: 10.1055/s-0037-1619274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
62
|
Cutolo G, Reise F, Schuler M, Nehmé R, Despras G, Brekalo J, Morin P, Renard PY, Lindhorst TK, Tatibouët A. Bifunctional mannoside–glucosinolate glycoconjugates as enzymatically triggered isothiocyanates and FimH ligands. Org Biomol Chem 2018; 16:4900-4913. [DOI: 10.1039/c8ob01128a] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The synthesis of glucosinolate–mannoside glycoconjugates combining both the structural features of a myrosinase substrate and a FimH ligand is described.
Collapse
|
63
|
Hirsh V, Tan E, Wu Y, Sequist L, Zhou C, Schuler M, Geater S, Mok T, Hu C, Yamamoto N, Feng J, O’Byrne K, Lu S, Huang Y, Sebastian M, Okamoto I, Dickgreber N, Shah R, Palmer M, Märten A, Massey D, Samuelsen C, Yang J. P3.01-075 Afatinib Dose Adjustment: Effect on Safety, Efficacy and Patient-Reported Outcomes in the LUX-Lung 3/6 Trials in EGFRm+ NSCLC. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
64
|
Park K, Tan E, O’Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang J, Schuler M, Yamamoto N, Sequist L, Wu Y, Zhou C, Ehrnrooth E, Märten A, Tang W, Paz-Ares L. P3.01-039 Sequential Afatinib-Osimertinib Therapy in EGFR Mutation-Positive (EGFRm+) NSCLC: Analysis of Time on Treatment and OS. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1480] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
65
|
Schuler M, Yang J, Sequist L, Wu Y, Zhou C, Geater S, Mok T, Tan E, Hu C, Yamamoto N, Feng J, O’Byrne K, Lu S, Hirsh V, Huang Y, Ellis S, Samuelsen C, Märten A, Fan J, Park K, Paz-Ares L. P3.01-026 Analysis of Long-Term Response to First-Line Afatinib in the LUX-Lung 3, 6 and 7 Trials in Advanced EGFRm+ NSCLC. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
66
|
Sequist L, Wu Y, Schuler M, Kato T, Yang J, Tanaka H, Hida T, Lu S, Park K, Paz-Ares L, Laurie S, Bennouna J, Moro Sibilot D, Märten A, Tang W, Ehrnrooth E, Yamamoto N, Nakagawa K. PS02.20 Subsequent Therapies Post-Afatinib Among Patients with EGFR Mutation-Positive (EGFRm+) NSCLC in LUX-Lung 3, 6 and 7. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.058] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
67
|
Shaw A, Kim D, Solomon B, Felip E, Riely G, Schuler M, Tan D, Chow L, Camidge D, Urban P, Ortmann C, Malet I, Mehra R. P1.01-012 Ceritinib in Anaplastic Lymphoma Kinase (ALK)+ NSCLC Patients Pretreated With Only Crizotinib: ASCEND-1 Subgroup Analysis. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.666] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
68
|
Schuler M, Nogova L, Heidenreich A, Tai D, Cassier P, Richly H, Cho B, Sayehli C, Navarro A, Bender S, Ocker M, Nogai H, Wagner A, Ince S, Ellinghaus P, Joerger M. Anti-tumor activity of the pan-FGFR inhibitor rogaratinib in patients with advanced urothelial carcinomas selected based on tumor FGFR mRNA expression levels. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx371.013] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
69
|
Al-Batran SE, Pauligk C, Homann N, Schmalenberg H, Kopp HG, Haag G, Luley K, Folprecht G, Probst S, Thuss-Patience P, Trojan J, Koenigsmann M, Lindig U, Pohl M, Kasper S, Möhler M, Goetze T, Schuler M, Jaeger E, Hofheinz R. Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: Updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx440.019] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
70
|
Joerger M, Soo R, Cho B, Navarro A, Sayehli C, Richly H, Tai D, Kim DW, Wolf J, Cassier P, Bender S, Ellinghaus P, Ince S, Rajagopalan P, Ocker M, Schuler M. A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors: Results from rogaratinib Phase-1 study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx367.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
71
|
Hamacher R, Kämpfe D, Ahrens M, Reuter-Jessen K, Schuler M, Schildhaus HU, Bauer S. PD-L1 inhibition – a new therapeutic opportunity in cutaneous angiosarcoma? Ann Oncol 2017. [DOI: 10.1093/annonc/mdx387.032] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
72
|
Kasper B, Reichardt P, Schuler M, Hohenberger P. Geriatric assessment of elderly chemotherapy-naïve patients treated with trabectedin for advanced soft tissue sarcomas (STS): The E-TRAB study of the German Interdisciplinary Sarcoma Group (GISG-13). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx387.050] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
73
|
Sequist L, Wu YL, Schuler M, Kato T, Yang JH, Tanaka H, Hida T, Lu S, Park K, Laurie S, Bennouna J, Moro Sibilot D, Märten A, Peil B, Ehrnrooth E, Yamamoto N, Nakagawa K. Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC in LUX-Lung (LL) 3, 6 and 7. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.051] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
74
|
Sahin U, Schuler M, Bauer S, Krilova A, Utsch M, Huber C, Türeci Ö. First-in-human study of IMAB362, an anti-claudin 18.2 monoclonal antibody, in patients with advanced gastroesophageal cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
75
|
Sauer R, Kiewe P, Desole M, Schuler M, Theissig F, Roth A, Mairinger T. Lymphozytäre Myokarditis unter Nivolumabtherapie bei metastasiertem klarzelligen Nierenzellkarzinom. DER PATHOLOGE 2017; 38:535-539. [DOI: 10.1007/s00292-017-0349-y] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|